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Epithelial Cells in the Hair Follicle Bulge do not
Contribute to Epidermal Regeneration after
Glucocorticoid-Induced Cutaneous Atrophy
Dmitry V. Chebotaev1, Alexander Y. Yemelyanov1, Robert M. Lavker1 and Irina V. Budunova1
One of the major adverse effects of glucocorticoid therapy is cutaneous atrophy, often followed by the
development of resistance to steroids. It is accepted that epithelial stem cells (SCs) located in the hair follicle
bulge divide during times of epidermal proliferative need. We determined whether follicular epithelial SCs and
their transit amplifying progeny were stimulated to proliferate in response to the chronic application of
glucocorticoid fluocinolone acetonide (FA). After first two applications of FA, keratinocyte proliferation in the
interfollicular epidermis (IFE) and hair follicles was minimal and resulted in significant epidermal hypoplasia.
We observed that a 50% depletion of the interfollicular keratinocyte population triggered a proliferative
response. Unexpectedly, less than 2% of the proliferating keratinocytes were located in the bulge region of the
hair follicle, whereas 82% were in IFE. It is known that cell desensitization to glucocorticoids is mediated via
temporary decrease of glucocorticoid receptor (GR) expression. We found that GR expression was significantly
decreased in IFE keratinocytes after each FA treatment. In contrast, many bulge keratinocytes retained GR in the
nucleus. Our results indicate that bulge keratinocytes, including follicular SCs, are more sensitive to the
antiproliferative effect of glucocorticoids than basal keratinocytes, possibly due to the incomplete process of
desensitization.
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INTRODUCTION
The epidermis is a continuously renewing tissue that is
replenished and repaired by epithelial stem cells (SCs).
Several lines of evidence indicate that during high prolif-
erative need, an important source of the proliferating cells in
the epidermis are follicular epithelial SCs that reside within a
specialized permanent segment of the outer root sheath of
hair follicle known as the bulge (Lavker and Sun, 2000; Ito
et al., 2005a; Morasso and Tomic-Canic, 2005). Bulge
epithelial SCs represent the most quiescent and long-lived
epithelial cells in skin, and as such can be experimentally
detected as label-retaining cells (LRCs)—cells that retain
labeled DNA for months (Morris and Potten, 1999; Taylor
et al., 2000). Because of their high proliferative capacity that
lasts throughout the lifetime of the organism, their multi-
potency, and strategic location within the specialized highly
protected niche (Cotsarelis et al., 1990; Morris and Potten,
1999; Blanpain et al., 2004; Morris et al., 2004), bulge
epithelial SCs have been viewed for years as the major source
of cells not only for the regeneration of hair follicles but also
for regeneration and repair of epidermis. Indeed, these
follicular epithelial SCs play an important role in the
epidermal regeneration after physical or chemical removal
of epidermis, superficial and full thickness skin wounding, or
burns (Taylor et al., 2000; Ito et al., 2005a; Levy et al., 2005).
Recent studies indicated that there are other classes of
cutaneous epithelial SC that are located in interfollicular
epidermis (IFE) and possibly in sebaceous gland (Ghazizadeh
and Taichman, 2001; Ito et al., 2005a; Levy et al., 2005;
Horsley et al., 2006).
Glucocorticoid hormones are potent inhibitors of keratino-
cyte proliferation and effective anti-inflammatory drugs,
which have been widely used for the treatment of hyper-
proliferative and inflammatory skin disorders such as atopic
dermatitis and psoriasis (reviewed in Perez et al., 2001;
Budunova et al., 2003; Schoepe et al., 2006). However, their
chronic use is accompanied by adverse effects. One of the
most prominent side effects of glucocorticoid therapy is skin
atrophy that affects different skin components and compro-
mises the barrier function of the skin. Glucocorticoid-induced
skin atrophy is characterized by a reduction in epidermal
thickness, a decreased number of keratinocytes, diminished
stratum corneum intercellular lipid lamella, loss of ground
substance, altered orientation and packing of collagen and
elastin fibers combined with a decreased cellularity in
dermis, elimination of subcutaneous fat, and loss of mast
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The cellular response to glucocorticoids is mediated
through the highly specific glucocorticoid receptor (GR)
(Hollenberg et al., 1985; Beato et al., 1995). Non-active GR
is bound to the heat-shock protein complex, and is
sequestered in the cytoplasm (Beato et al., 1995; Yudt and
Cidlowski, 2002; De Bosscher et al., 2003). Following ligand
binding, the GR dissociates from the chaperones and forms
homodimers, which enter the nucleus. There are two major
mechanisms of gene regulation by the GR (De Bosscher et al.,
2003). The first is the positive transcriptional regulation of
genes (transactivation) requiring the binding of the GR
homodimer to DNA sequences called glucocorticoid-re-
sponse elements in the promoter or enhancer region of
glucocorticoid-responsive genes. The second is negative gene
regulation (trans-repression) mediated via GR binding to
negative glucocorticoid-response elements or via cross-talk
with other transcription factors, including activator protein-1
(AP-1), NF-kB, and others, resulting in the inhibition of the
partner transcription factor activity (Adcock, 2001; De
Bosscher et al., 2003; Necela and Cidlowski, 2004; Schacke
et al., 2004; Yemelyanov et al., 2007). Recently an additional
mechanism of indirect gene regulation by the GR was
discovered, where GR blocks mitogen-activated protein
kinases (Kassel et al., 2001; Imasato et al., 2002; Bruna
et al., 2003; Necela and Cidlowski, 2004; Yemelyanov et al.,
2007). We and others showed that GR is expressed in rodent
and human IFE (Karstila et al., 1994; Budunova et al., 1997;
Perez et al., 2001; Ito et al., 2005b). However, GR expression
in a bulge area of hair follicles has not been well studied.
To determine whether bulge keratinocytes (including
follicular epithelial SCs) are involved in epidermal repair
after development of steroid-induced skin atrophy, we
studied the GR expression in the bulge and the kinetics of
bulge-located keratinocyte proliferation, as well as IFE, when
15, 30, and 50% epidermal hypoplasia was achieved. We
report herein that bulge keratinocytes express GR and are
sensitive to glucocorticoid-induced growth inhibition. Un-
expectedly, bulge keratinocytes developed resistance to
glucocorticoids more slowly than basal keratinocytes, and
did not significantly contribute to the reparation of epidermis
after glucocorticoid-induced skin atrophy.
RESULTS
GR is expressed in hair follicular bulge keratinocytes
It was shown that GR is prominently expressed in IFE (Karstila
et al., 1994; Budunova et al., 1997; Perez et al., 2001; Ito
et al., 2005b). However, the GR expression in the bulge area
of hair follicles, a region that is enriched in follicular
epithelial SCs, has not been well studied. To assess GR
expression in this population of keratinocytes as well as in
basal keratinocytes, we isolated bulge keratinocytes and
basal keratinocytes from six mice, whose hair follicles were
in the telogen stage of the hair cycle, by FACS analysis using
previously reported bulge surface markers CD34 and a6-
integrin (Trempus et al., 2003; Blanpain et al., 2004; Tumbar
et al., 2004). Two-color FACS analysis allowed us to isolate a
discrete, highly homogenous fraction of bulge keratinocytes:
the purity of CD34þ /a6-integrinþ -sorted keratinocytes was
B90%, as confirmed by post-sort FACS analyses (Chebotaev
et al., 2007). We used data of our bulge/IFE keratinocyte gene
array (Chebotaev et al., unpublished data) to compare the
expression of GR in these two keratinocyte populations
isolated from skin of the same animals. On gene array, the
expression of Nr3c1 (gene symbol for GR) was 1.6-fold
higher (P-value¼ 0.0002) in bulge keratinocytes. We
confirmed these data by quantitative real-time PCR that
revealed that the expression of GR mRNA in bulge cells was
30–40% higher.
To study the expression of GR protein in bulge keratino-
cytes, we used double immunofluorescence of skin sections
with anti-GR and anti-CD34 Abs, as CD34 expression defines
bulge boundaries. We found that GR was equally expressed
in IFE, in the upper part of hair follicle, and in the bulge
region of the hair follicle (Figure 1). GR-related immuno-
reactivity was localized not only in cytoplasm but also in the
nuclei of keratinocytes, especially in the hair follicles
(Figure 1). This partial nuclear localization of GR is possibly
due to receptor activation by endogenous glucocorticoids
synthesized in hair follicles (Ito et al., 2005b).
GR expression and function in keratinocytes during topical
application of fluocinolone acetonide
One of the mechanisms of cell desensitization to the effect of
glucocorticoids is mediated via a negative feedback loop that
results in the temporary decrease of GR expression upon
treatment with hormone (Zong et al., 1990; Oakley and
Cidlowski, 1993; Budunova et al., 1997). Thus, to choose the
most effective treatment regimen to produce a glucocorti-
coid-induced epidermal hypoplasia, we identified the time of
GR expression recovery after topical application of the
synthetic glucocorticoid fluocinolone acetonide (FA). Wes-
tern blotting (Figure 2a) indicated that the level of GR protein
was significantly decreased 24 hours after FA application, but
returned to control level 48 hours after treatment. Thus, we
have chosen the intermittent regimen of treatment and
applied FA topically every 48 hours for our experiments.
To further confirm the validity of the intermittent regimen,
we assessed the GR function in keratinocytes at the beginning
and end of FA applications. For this, we performed Northern
blot analysis of expression of the endogenous glucocorticoid-
responsive gene Metallothionein I (Mt1). In our previous
work we showed that Mt1 is a reliable endogenous GR
reporter, whose expression strongly depends on GR activity
(Budunova et al., 1997). We found that Mt1 expression was
induced at an equal level after first and fourth applications of
FA (Figure 2b), indicating that GR was fully functional during
the course of skin treatment.
Effect of intermittent skin treatment with glucocorticoid on skin
morphology, epidermal cellularity, and keratinocyte
proliferation
In the skin of F1 C57BlxDBA control mice (8 weeks old)
treated with vehicle, the 5-bromo-2-deoxyuridine (BrdU)
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labeling index was 2.5%. This correlates well with the usual
2–4% proliferation rate of basal keratinocytes in the IFE of
adult mouse and human epidermis (Budunova et al., 1997;
Jensen and Lavker, 1999). The proliferation rate of keratino-
cytes in hair follicles was B1.5% (B1 BrdU-positive cell/
follicle), as mice follicles were in the telogen (resting) stage of
the hair cycle.
After the first and second FA applications, the proliferation
of keratinocytes in the IFE and in hair follicles was almost
completely blocked. The proliferative rate of the basal
keratinocytes in IFE decreased to 0.3%, and to 0.1% after
the first and second FA applications, respectively, and there
were almost no BrdU-positive cells in hair follicles (see
below). Likewise, the proliferation of cells in the sebaceous
gland was also strongly inhibited (data not shown).
The dramatic changes in proliferation of keratinocytes and
other skin cells during the intermittent regimen of glucocorti-
coid treatment resulted in a significant skin atrophy mani-
fested by the loss of thickness of all the cutaneous
compartments. After the fourth FA application, the IFE was
markedly thin and was comprised of a thin, loosely formed
basal layer, and in some places by a basal and a granular
layer (Figure 3). The keratinocytes in basal compartment were
flat with elongated nuclei, and were oriented horizontally
along the basement membrane, resembling the differentiated
keratinocytes in the upper spinous/granular layers in control
skin. The hair follicles at this time of FA treatment were in the
telogen phase of hair cycle (Figure 3), and no extension of the
secondary hair germ was observed. We also noticed a
regression of the sebaceous glands.
We measured the epidermal thickness and epidermal
cellularity (the number of basal keratinocytes/mm of IFE)
during the course of treatment and found changes that were
consistent with their phenotype. The thickness of epidermis
and number of basal keratinocytes were reduced after the
second FA treatment by 30 and 20%, respectively (Figure 4a).
After the fourth FA application, a 50% decrease in both
epidermal thickness and basal keratinocyte number was
noted (Figure 4a).
At 50% epidermal hypoplasia (50% depletion in the
number of basal keratinocytes), some keratinocytes and
other skin cells such as sebocytes started to develop
resistance to the growth inhibitory effect of glucocorticoids
and began to proliferate (Figure 5); a phenomenon known as
tachyphylaxis.
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Figure 1. Coexpression of GR and CD34 marker in bulge keratinocytes
in hair follicle. (a) Skin sections from control animals were double
immunostained with anti-GR Ab (green) and anti-CD34 Ab (red). Sections
were analyzed by fluorescent microscope. The left panel shows coexpression
of GR and CD34 in bulge keratinocytes (bulge area is circled). The top right
panel shows GR expression in hair follicle and IFE; the bottom right panel
shows CD34 expression in hair follicle and IFE. (b) Skin sections from the
same animals were stained only with FITC- and Cy3-conjugated secondary
Abs (left and middle panels, negative control), and counterstained with DAPI
to identify the nuclei. Note: GR is well expressed in bulge and IFE, and is
localized both in the nuclei and in the cytoplasm of keratinocytes. In the
bulge GR is coexpressed with the marker CD34.
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Figure 2. Expression and function of GR in epidermis after glucocorticoid
treatment. (a) Western blot analysis of GR expression. Animals were treated
with FA or acetone (control) once. The whole cell protein extracts were
prepared from epidermis 24 and 48 hours after FA application, and used for
Western blot analysis of GR expression. Probing with anti-a-actin Ab was
used as control for protein loading. (b) Northern blot analysis of expression of
GR-responsive gene Mt1. Animals were treated with FA every second day
(intermittent regimen). Twenty-four hours after the first and fourth FA
applications, total RNA from epidermis was isolated and used for Northern
blot analysis of Mt1 expression. Probing with 7S ribosomal RNA was used to
control RNA loading. Note: Mt1 expression was induced at an equal level
after first and fourth applications of FA indicating that GR was fully functional
during the course of skin treatment with FA.
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It is known that follicular epithelial SCs cells and their
progeny are important for repopulating the epidermis after
injury (Taylor et al., 2000; Ito et al., 2005a; Levy et al., 2005).
Thus, we expected to find an induction of proliferation of
bulge keratinocytes in response to the significant glucocorti-
coid-induced cutaneous hypoplasia. Unexpectedly, analysis
of 4300 BrdU-positive keratinocytes in skin sections of
animals treated with FA for four times revealed that more
than 80% of proliferating keratinocytes were located in IFE
(Figure 6a and b). In contrast, only 16% of proliferating cells
were found in the upper part of hair follicle, and less than 2%
in the bulge of hair follicles. Moreover, the proliferation rate
of keratinocytes in IFE after the fourth application of FA
returned to the control level control (3.270.4% in FA-treated
skin, and 2.470.3% in control skin; Figure 6a). At the same
time, proliferation of keratinocytes in hair follicles reached
only 25% of control proliferation levels after the fourth FA
application (Figure 6a). This result suggests that cells in hair
follicle are more sensitive to the growth inhibitory effect of
corticosteroids, and gain resistance to hormone with the
significant delay.
We initially expected that the proliferation of follicular SCs
would be stimulated during the restoration of the epidermis
following glucocorticoid-induced cutaneous atrophy. Thus,
we assessed bulge epithelial SC proliferation at the time of
50% epidermal hypoplasia using a previously described
double labeling approach (Lehrer et al., 1998; Taylor et al.,
2000). For this we injected newborn pups subcutaneously
with BrdU, twice a day for 3 days. This protocol resulted in
B100% of the keratinocytes incorporating BrdU 24 hours
after the last injection. Following an 8-week chase, the
rapidly cycling TA cells in the upper part of outer root sheath
and in IFE divided, diluted the BrdU label, and underwent
terminal differentiation. At the same time, most of the
quiescent BrdU-stained cells (LRCs) resided in the bulge
region of the hair follicles. To assess the proliferation of LRC
in adult skin, mice bearing LRCs were injected with
[3H]thymidine 1 hour before skin was harvested. [3H]Thymi-
dine was mostly incorporated by keratinocytes in IFE, where
hardly any LRCs were localized. We did not find any
proliferating ([3H]thymidine positive) LRCs in the bulge area
after four FA applications (data not shown).
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Figure 3. Topical treatment with glucocorticoid FA induced strong skin
atrophy in mice. Animals were treated with acetone (control) or FA
(intermittent regimen), and skin was harvested 24 hours after the last FA
application. Skin sections were stained with hematoxylin/eosin. (a, c) Control
skin after acetone treatment. (b, d) Skin after FA treatment. Note that
intermittent regimen of FA treatment resulted in significant skin atrophy.
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Figure 4. Quantitative analysis of epidermal hypoplasia induced by FA in
mouse skin. Animals were treated with acetone (control) or with FA. Skin was
harvested, stained with hematoxylin/eosin, and the number of basal cells and
the thickness of epidermis were determined as described in Materials and
Methods. A total of 40–50 microscopic fields of view were examined in each
skin sample. A total of three to four samples from individual animals in each
experimental group were used for analysis. The changes in FA-treated
epidermis were calculated as percentage to control, and the results of
representative experiment are presented as mean7SD. (a) Intermittent
regimen of treatment. Skin was harvested 24 hours after the first, second, and
fourth FA applications. (b) Continuous regiment of treatment. Skin was
harvested 1, 2, 3, 4, and 5 days after the last FA application. Note that
intermittent regimen of FA treatment resulted in more pronounced epidermal
hypoplasia.
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Effect of continuous skin treatment with glucocorticoid on
epidermal cellularity and keratinocyte proliferation
To ensure that we did not miss the optimal time of bulge
keratinocyte proliferation during the intermittent treatment
regimen with FA, we treated mice with FA for four
consecutive days, and studied keratinocyte proliferation 1,
2, 3, 4, and 5 days after the last steroid application. The
epidermal hypoplasia that resulted from this continuous
treatment was less pronounced than hypoplasia induced by
intermittent FA treatment. After the last glucocorticoid
application, epidermal thickness was reduced by 35% when
FA was applied every 24 hours, compared to a 55% reduction
when FA was applied every other 24 hour (Figure 4b).
Accordingly, the number of basal keratinocytes was reduced
by 25% after the daily treatment with FA, and by 50% after
intermittent treatment with FA. This finding probably reflects
that fact that GR expression is downregulated when FA
applied every 24 hours (Figure 2a).
The epidermal hypoplasia induced by continuous FA
treatment was persistent. Five days after the last FA
application, the epidermal thickness was still reduced by
35% compared to untreated epidermis (Figure 4b). Appa-
rently a 35% reduction in epidermis thickness and a 25%
reduction in basal layer cellularity (Figure 4b) were not
sufficient to induce keratinocyte proliferation. We did not
observe any BrdU-labeled keratinocyte 1–3 days after the last
FA application. However, because the epidermal hypoplasia
was persistent, activation of keratinocytes to proliferate
eventually occurred. A few BrdU-positive keratinocytes were
observed on the fourth day after FA treatment was stopped,
and on the fifth day after the treatment, a significant number
of keratinocytes were in S-phase. The analysis of 4170
BrdU-positive keratinocytes on skin sections of animals
treated continuously with FA again showed that B70% of
proliferating keratinocytes were located in IFE, B24 % were
located in the upper part of hair follicle, and less than 5%
were found in the bulge (Figure 6b).
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Figure 6. Preferential localization of BrdU-positive keratinocytes in IFE at
the stage of resistance to FA. (a) Number of BrdU-positive keratinocytes in
hair follicles and in IFE during the intermittent regimen of FA treatment.
Animals were treated as indicated in legend for Figure 5a, and injected
intraperitoneally with BrdU, 1 hour before skin was harvested. BrdU-positive
keratinocytes were identified by immunostaining, and their localization was
determined. The number of BrdU-positive keratinocytes in IFE and hair
follicles is presented as percent to the number of BrdU-positive keratinocytes
in IFE and hair follicles in control skin. The mean7SD was calculated for four
individual skin samples in one representative experiment. In each sample,
a total of 40–50 individual fields of view were examined. (b) Localization of
BrdU-labeled keratinocytes did not depend on the regimen of skin treatment
with FA. Animals were treated with acetone (control) or FA. Skin was
harvested 24 hours after the last FA treatment (intermittent regimen) or 5 days
after the last FA treatment (continuous regimen). The number of BrdU-positive
keratinocytes in IFE, upper part of hair follicle, and the bulge or hair follicles is
presented as percentage to the total number of examined BrdU-positive
keratinocytes. The mean7SD was calculated for four individual skin samples
in one representative experiment. In each sample, a total of 40–50 individual
fields of view were examined. Note that B70–85% of proliferating
keratinocytes are located in IFE after both regimens of FA treatment.
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Figure 5. Effect of chronic skin treatment with FA on keratinocyte
proliferation. Animals were treated with acetone (control) or with FA
(intermittent regimen of treatment) and injected intraperitoneally with BrdU
1 hour before skin was harvested. BrdU-positive cells were identified by
immunostaining. (a) Control; (b) FA1 (24 hours after first FA application);
(c) FA4 (24 hours after fourth FA application). BrdU-positive cells are
indicated by arrows. Note that in FA 4-treated skin, most BrdU-positive
keratinocytes are localized in the IFE.
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Differential regulation of GR by glucocorticoid in keratinocytes
in hair follicle bulge and IFE
As we have discussed above, one of the well-known
mechanisms of keratinocyte desensitization to glucocorti-
coids is mediated via the temporary decrease of GR
expression. In our previous and current experiments, we
revealed downregulation of GR expression at mRNA and
protein levels (Budunova et al., 1997; Figure 2a). For those
studies we used RNA and protein samples from epidermis
physically separated from dermis by scraping (see Materials
and Methods). This procedure allows isolation of keratino-
cytes from IFE and the upper part of hair follicles but not from
the bulge. Thus, to understand the dynamics of GR expression
in bulge keratinocytes after FA treatment, we performed
immunostaining. The results of immunostaining revealed the
striking difference in GR regulation by FA in two keratinocyte
populations. Indeed, in control skin GR was well expressed in
follicular and IFE keratinocytes and was localized in
cytoplasm as well as in the nuclei (Figure 7a). Twenty-four
hours after the first FA application, the overall expression of
GR in both keratinocyte populations was significantly
decreased compared to control skin (Figure 7c). This decrease
correlates well with the data of Western blotting (Figure 2a).
Surprisingly, in comparison to IFE keratinocytes, in which
both nuclear and cytoplasm GR expression was reduced,
many bulge keratinocytes retained GR in the nuclei (black
arrows in Figure 7c, insets). This finding suggests that GR
desensitization was less complete in the bulge than in IFE.
The immunostaining of skin treated with FA four times
(intermittent regimen, 24 hours after the last treatment) further
confirmed this observation (Figure 7d).
DISCUSSION
Recent studies clearly indicated that there are several classes
of epithelial SCs in skin. The primary source of multipotent
SCs is the follicular epithelial SCs located in the bulge
(reviewed by Blanpain and Fuchs, 2006; Ito et al., 2005a;
Morasso and Tomic-Canic, 2005). The capability of isolated
bulge cells to reconstitute both hair follicle and epidermis has
led to the conclusion that these cells are the ultimate source
for the regeneration and maintenance of both hair follicles
and IFE (Taylor et al., 2000; Blanpain et al., 2004; Morris
et al., 2004; Tumbar et al., 2004). Indeed, these cells have
been shown to play an important role in the repair of the
epidermis after physical removal, wounding, and burns
(Taylor et al., 2000; Ito et al., 2005a; Levy et al., 2005).
The secondary source are epidermal SCs located through-
out the basal layer of IFE, that have an epidermal-regenerative
capacity (Cotsarelis et al., 1999; Li et al., 2004), but are
somewhat less multipotent than the bulge SCs (Morasso and
Tomic-Canic, 2005; Blanpain and Fuchs, 2006). Epithelial SC
lineage studies using genetic approaches clearly showed that
bulge keratinocytes (SCs) do not usually contribute to the
maintenance of the normal IFE (Ghazizadeh and Taichman,
2001; Ito et al., 2005a; Levy et al., 2005).
The experiments presented here were designed to
determine whether (i) bulge keratinocytes are stimulated to
proliferate and thus are involved in the restoration of
epidermal homeostasis after the development of glucocorti-
coid-related skin atrophy, and (ii) what level of epidermal cell
loss triggers follicular SC proliferation. Using different regi-
mens of glucocorticoid treatment, we were able to achieve
incremental 15, 30, and 50% epidermal hypoplasia, and
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Figure 7. Changes in GR expression in different keratinocyte populations after FA treatment. Animals were treated with acetone (control) or
FA (intermittent regimen of treatment as in legend for Figure 5a). Skin was harvested 24 hours after last FA application, fixed, and used for GR immunostaining.
(a) Control; (c) FA 1 (24 hours after first FA application); (d) FA 4 (24 hours after fourth FA application). (b) negative control for GR immunostaining
(acetone-treated skin was incubated with rabbit serum instead of anti-GR Ab). GR-positive nuclei are indicated by black arrows; GR-negative nuclei are
indicated by white arrows. Note: in control skin, GR has both nuclear and cytoplasmic localizations in bulge and IFE keratinocytes. In FA-treated skin, most
keratinocytes in IFE do not express GR in the nucleus, while bulge keratinocytes retain GR in the nucleus.
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showed that only a 50% depletion of the interfollicular
keratinocyte population triggers a proliferative response.
Unexpectedly, more than 80% of the keratinocytes that
entered S-phase in response to epidermal hypoplasia were
located within IFE, possibly indicating the involvement of the
epidermal as opposed to the follicular epithelial SCs in this
process. We hypothesize that BrdU-positive keratinocytes
that started to proliferate in IFE are either epidermal SCs or
their early TA cell progeny. Unfortunately, these epidermal
SCs are much less well characterized than follicular epithelial
SCs, in terms of the surface marker expression. Thus, direct
confirmation of this idea will require the development of
reliable epidermal SC markers.
Little is known about the signals that induce epithelial SCs
to proliferate during epidermal renewal and repair. For
example, during skin wounding, multiple pro-proliferative
cytokines and growth factors are released from the keratino-
cytes and fibroblasts, including IL-1, tumor necrosis factor-a,
epidermal growth factor (EGF), and others (Morasso and
Tomic-Canic, 2005). Glucocorticoids are known to inhibit
wound healing via different mechanisms, including the
inhibition of keratinocyte proliferation (Lehmann et al.,
1983; Morasso and Tomic-Canic, 2005; Schoepe et al.,
2006). The negative cross-talk between GR and pro-
proliferative signaling mediated by cytokines and growth
factors, including EGF, is also well known (Morasso and
Tomic-Canic, 2005; Yemelyanov et al., 2007). Thus, even
though the role of specific pro-proliferative factors in the
initiation of follicular and epidermal SC proliferation remains
to be investigated, it is reasonable to assume that the negative
interaction between GR and pro-proliferative factor signaling
may underlie the inhibition of SC proliferation, and con-
tribute to the inhibition of wound healing by corticosteroids.
In the light of the strong growth inhibitory effect of
glucocorticoids on keratinocytes, the experimental design
used in our experiments to induce proliferation of epithelial
SCs was different compared to wounding or mechanical
removal of epidermis. In our experiments, epidermal SCs not
only respond to the dramatic decrease in epidermal
cellularity but also overcome the growth inhibitory effect of
steroids.
One of the known temporary mechanisms of desensitiza-
tion of cells to the effect of glucocorticoids is mediated via
inhibition of GR expression upon treatment with hormone
(Zong et al., 1990; Oakley and Cidlowski, 1993; Budunova
et al., 1997). Our results indicate that in contrast to IFE, GR
downregulation in bulge keratinocytes is incomplete. Nuclear
localization of GR suggests that it remains active as a
transcription factor and continues to negatively control
proliferation of bulge keratinocytes. However, the experi-
mental proof of the above statement requires the direct
assessment of GR functional activity and evaluation of
downstream GR target genes in the specific keratinocyte
populations. Overall, we hypothesize that the inability of
bulge keratinocytes, including follicular epithelial SC, to
develop tachyphylaxis to glucocorticoids is partially the
consequence of insufficient mechanisms of desensitization in
this cell population.
Our recent results obtained in Keratin5.GR transgenic
animals provide additional evidence that follicular epithelial
SCs are highly sensitive to GR signaling. We found that the
number of putative follicular epithelial SCs and their
clonogenicity was strongly reduced in Keratin5.GR trans-
genic animals that express high level of GR in basal
keratinocytes in IFE and in the bulge (Chebotaev et al.,
2007). It is interesting that in contrast, the number of basal
keratinocytes and their proliferation in intact adult skin of
K5.GR mice did not change compared to wild-type litter-
mates (Chebotaev et al., 2007).
There are other physiological and pathological conditions
in skin that are associated with the development of
glucocorticoid resistance. For example, keratinocytes in
neonatal skin and skin tumors are resistant to growth
inhibition by glucocorticoids (Slaga et al., 1978; Budunova
et al., 1997). It is interesting that in all these cases the
development of resistance to steroids was associated with
intensive proliferation and expansion of the basal keratino-
cyte compartment (which obviously involved proliferation of
normal and transformed epithelial SCs and their early
progeny). These data highlight the important role of GR in
the regulation of proliferation of cutaneous epithelial SCs.
They also suggest that to improve the overall outcome of
treatment with glucocorticoids, the optimization of the
treatment regimen based on the dynamics of GR expression
and the dynamics of development of glucocorticoid resis-
tance (tachyphylaxis) should be considered.
In conclusion, our results suggest that bulge keratinocytes
do not significantly contribute to the restoration of the
epidermis after glucocorticoid-induced skin atrophy, and
highlight the potential role of SCs that reside in IFE as a major
source for the regeneration of the epidermis during the
steroid-induced hypoplasia. Thus, our results support the
recent evidence that epidermal and follicular epithelial SCs
are distinct cell populations with different properties and
roles in the skin homeostasis and regeneration. The under-
standing of the effects of glucocorticoid on different classes of
cutaneous epithelial SCs, and the mechanism(s) of SC
resistance to glucocorticoids will allow the development of
therapeutic approaches to treat/prevent glucocorticoid-
induced skin atrophy, which is one of the major adverse
effects of chronic steroid usage.
MATERIALS AND METHODS
Animals and treatments
B6D2 (F1 C57BlDBA) females were obtained from Jackson
Laboratory (Bar Harbor, ME). Seven to eight weeks old animals in
the telogen stage of the hair cycle were shaved, and treated 3 days
later with glucocorticoid FA (Sigma, St Louis, MO). FA was applied
topically (5mg/animal) in 200ml acetone. Control animals were
treated with acetone only.
To study the effect of FA on skin atrophy and keratinocyte
proliferation, we used two different regimens. During the inter-
mittent regimen, animals were treated with FA four times every
second day and killed by CO2 inhalation followed by cervical
dislocation 24 hours after the first, second, and fourth FA applica-
tions. During the continuous regiment, animals were treated with FA
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four times for four consequent days, and killed 1, 2, 3, 4, and 5 days
after the last FA application. All animals were injected intraper-
itoneally with BrdU (Sigma, St Louis, MO) solution in phosphate-
buffered saline (50 mg/g of animal weight) 1 hour before they were
killed. All animal experiments were performed in compliance with
ACUC protocol approved by the Northwestern University Animal
Care and Ethics Committee.
Morphometric analysis of epidermis
Mice were treated with FA using intermittent and continuous
regimens, as described above. Dorsal skin was harvested, fixed in
formalin, processed to 5mm paraffin sections, stained with hematoxy-
lin/eosin, and used for morphometric analyses. The number of basal
keratinocytes was calculated per 1 mm of IFE. The thickness of
epidermis was assessed using Axioplan2 microscope software (Carl
Zeiss, Oberkochen, Germany). A total of 40–50 individual fields of
view were examined in each skin sample, with three to four samples
from individual animals in each experimental group. Ten measure-
ments of epidermis thickness were performed randomly in each field
of view. The number of basal keratinocytes and the epidermal
thickness in FA-treated animals are presented as the percentage of
those parameters in control animals.
Immunostaining
Formalin-fixed mouse skin samples were used for BrdU, GR, and
CD34/GR double immunostaining. After antigen retrieval (10 min-
utes at 901C in citric buffer, pH 6.0), the tissues were blocked with
10% horse serum in phosphate-buffered saline. For BrdU staining,
tissues from control and FA-treated animals were incubated with
mouse monoclonal anti-BrdU Ab (BD Biosciences, San Jose, CA),
followed by biotinylated secondary anti-mouse IgG from Mouse-on-
mouse kit and ABC reagent from Standard VECTASTAINs Elite ABC
kit (Vector Laboratories, Burlingame, CA). Immunostaining was
visualized with DAB chromogen (Vector Laboratories, Burlingame,
CA), and tissues were counterstained with Gill’s hematoxylin (Vector
Laboratories, Burlingame, CA). The number of BrdU-positive cells
was calculated as indicated in the figure legends. For GR staining,
tissues were incubated with rabbit anti-GR Ab (Santa-Cruz Biotech-
nology, Pasadena, CA) followed by the procedures described above.
For CD34/GR double immunofluorescence, tissues from control
animals were incubated with rabbit anti-GR Ab (Santa-Cruz
Biotechnology, Pasadena, CA) and rat anti-mouse CD34 Ab (BD
Pharmingen, San Diego, CA), followed by Cy3-conjugated donkey
anti-rat and FITC-conjugated goat anti-rabbit secondary Abs (both
from Jackson ImmunoResearch Laboratory Inc., West Grove, PA).
Sections were counterstained with 40,6-diamidino-2-phenylindole
(DAPI, Vector Laboratories, Burlingame, CA) to identify the nuclei.
Immunofluorescence was analyzed using a fluorescent microscope
(Axioplan2, Carl Zeiss, Germany).
Detection of proliferation of LRCs by double labeling approach
To assess the proliferation of putative SCs in the bulge, we used a
double labeling approach as described previously (Lehrer et al.,
1998; Taylor et al., 2000). To tag the LRCs, we injected newborn
mice (postnatal day 3–5) subcutaneously with BrdU (50 mg/g body
weight), twice daily for 3 days. Eight weeks later, BrdU-labeled mice
were used for the intermittent FA treatment (as described above)
followed by the detection of proliferation of LRC. For this purpose
the FA-treated animals were injected with tritiated thymidine
(H3TdR, 10 mCi/g body weight) 24 hours after the first and the last
FA application and killed 1 hour following injection. Dorsal skin was
harvested, fixed in 70% ethanol–glycine solution, and processed to
5 mm paraffin sections. Slides were stained with anti-BrdU Ab and
alkaline phosphatase-labeled secondary Ab (both from Boehringer,
Indianapolis, IN), followed by visualization with red substrate
(Vector Laboratories, Burlingame, CA), as described previously
(Lehrer et al., 1998). H3TdR-positive cells were detected by
autoradiography. Keratinocytes with intensive BrdU signal in the
nuclei 8 weeks after injections were considered LRCs. Keratinocytes
containing 45 silver grains over a nucleus were considered to be
H3TdR labeled. The number BrdU/H3TdR double labeled keratino-
cytes was counted in skin sections, with bulge areas longitudinally
sectioned through the center of the hair follicles (a total of 20–30 hair
follicles from three individual animals/group).
DNA array and quantitative PCR analysis of GR expression in
bulge keratinocytes
SC-enriched bulge keratinocytes were isolated by FACS analysis
using CD34 and a6-integrin surface markers, as previously described
(Trempus et al., 2003; Morris et al., 2004; Chebotaev et al., 2007).
Briefly, keratinocytes obtained from the dorsal skin of mice at the
telogen stage of hair cycle were stained with FITC-conjugated rat
anti-mouse a6-integrin Ab and biotin-conjugated rat anti-mouse
CD34 Ab, followed by treatment with phycoerythrin-conjugated
streptavidin (all reagents were from BD Pharmingen, San Jose, CA).
a6-integrinþ /CD34þ SC-enriched bulge keratinocytes and a6-
integrinþ /CD34 basal keratinocytes were isolated using a MoFlo
cell sorter (Dako, Fort Collins, CO), using Summit software (Dako),
and purity of sorted cells was determined by post-sort FACS.
Total RNA was extracted from both keratinocyte populations, and
purified by PicoPureTM RNA Isolation kit (Arcturus, Mountain View,
CA). Quality of RNA was assessed by Bioanalyzer 2100 (Agilent
Technologies Inc., Palo Alto, CA) and quantified spectrophoto-
metrically (ND-1000, Nanodrop, Wilmington, DE). RNA samples
from three individual sets of SCs and basal keratinocytes were used
for two-round amplification and hybridization to Affymetrix Mouse
430 2.0 Arrays (Affymetrix, Santa Clara, CA). RNA amplification,
labeling, hybridization, and data analysis were performed as
described earlier (Chebotaev et al., 2007). Robust probe-set
summary of the log-transformed probe-level data was used to
perform the t-test. Genes with a P-valuep0.05 and a fold change
X1.5 were considered statistically significant.
TaqMan real-time quantitative PCR was performed using ABI
Prism 7900 (Applied Biosystems, Foster City, CA). Reverse transcrip-
tion and amplification of total RNA (1–3 ng) from a6þCD34þ
keratinocytes were accomplished in a one-step format with a
TaqMans One-Step real time reverse transcription PCR (RT–PCR)
Master Mix Reagents kit (Applied Biosystems, Foster City, CA) and
with predesigned/pre-optimized GR-specific TaqMan primers and
probe from TaqMans Gene Expression Assays kit with mouse
GAPDH as endogenous control (Applied Biosystems, Foster City, CA).
Western blot analysis
To study the effect of FA on GR expression in epidermis, animals
were treated with FA once, and killed 24 and 48 hours after the
treatment. Epidermis was isolated from dermis by scraping on ice
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with razor blade, and the whole cell protein extracts were prepared
using radioimmunoprecipitation (RIPA) buffer, as described pre-
viously (Yemelyanov et al., 2007). Proteins were resolved by
SDS–PAGE on 10% gels, and transferred to nitrocellulose mem-
branes (BioRad, Hercules, CA). Membranes were blocked with 5%
Blotto in tris-buffered saline, and incubated with anti-GR polyclonal
rabbit Ab (Santa-Cruz Biotechnology, Pasadena, CA) overnight at
41C, followed by treatment with peroxidase-conjugated anti-rabbit
IgG secondary Abs (Cell Signaling Technology, Beverly, MA). ECL
reagent (Amersham Pharmacia Biotech, Uppsala, Sweden) was used
for the band visualization. To verify equal loading and adequate
transfer, the membrane was probed with anti-a-actin Abs (Santa Cruz
Biotechnology, Pasadena, CA).
Northern blotting
Animals were treated with FA using the intermittent regimen.
Twenty-four hours after the first and fourth FA applications,
epidermis was separated by scraping and total RNA was isolated
from epidermis with TRI reagent (Molecular Research Center Inc.,
Cincinnati, OH). Northern blots (20 mg/lane) were probed for
expression of Mt1 as described previously (Budunova et al., 1997).
DNA probes were labeled by random primed reactions (Redipri-
meTMII, Amersham, Piscataway, NJ) using the complete coding
sequence of murine Mt1 (kind gift from Dr R. Lebovitz, Baylor
College of Medicine, Houston, TX) as template.
Statistical analysis
There were three to four animals in each experimental group, and all
experiments were repeated at least two times. Mean and standard
error values for proliferation and morphometric analyses were
calculated using Microsoft Excel software and compared using
paired Student’s t-test. Statistical analysis of GR expression in bulge
and basal keratinocytes is described above.
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